臨床研究等提出・公開システム

A drug-drug interaction study with TS-172 in healthy adult male subjects

A drug-drug interaction study with TS-172 in healthy adult male subjects

Seiji Development Mita

Taisho Pharmaceutical Co., LTD.

3-24,1, Takada, Toshima-Ku, Tokyo

shu_chiken@taisho.co.jp

Management Development Development Headquarters

Taisho Pharmaceutical Co., LTD.

3-24,1, Takada, Toshima-Ku, Tokyo

+81-3-3985-1413

shu_chiken@taisho.co.jp

Not Recruiting

Mar. 13, 2025

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Japanese healthy adult males whose age is >=18 and <40 years at the time of obtaining informed consent
2. Subjects whose body mass index is >=18.5 and <25.0 at the screening test
3. Subjects who are judged by a principal investigator or a sub-investigator to be eligible for participation in the study based on the results at the screening test and before administration of the drugs used in the study
4. Subjects who have been informed of the clinical trial, understand the details of the trial, and give their written consent prior to participation in the trial

1. Subjects with medical history ineligible for participation in the study such as of respiratory, cardiovascular, gastrointestinal, hepatic, renal, urologic, endocrine, metabolic, hematologic, immunologic, dermatologic, neurologic, or psychiatric diseases
2. Subjects with medical history of disease (e.g., stomach or intestinal ulcers) or surgery (e.g., gastrectomy, gastric bandage, gastric bypass) that may affect the absorption of the drugs used in the study
3. Subjects who have been hospitalized with any treatment or undergone surgery within 12 weeks prior to receiving the drugs used in the study
4. Subjects with medical history of drug allergies (limited to severe symptoms such as anaphylaxis) or significant allergic predispositions (e.g., asthma that requires treatment)
5. Subjects who have used medications (including over-the-counter drugs) within 2 weeks prior to receiving the drugs used in the study

Male

Hyperphosphatemia

Part A: Oral single administration of triazolam 0.25 mg at single administration phase, followed by an oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
Part B: Oral single administration of TS-172 20 mg at single administration phase, followed by an oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase

Drug concentration in plasma

+81-92-283-7701

Feb. 28, 2025

No

none